HUE061429T2 - Új botulinum neurotoxin és származékai - Google Patents
Új botulinum neurotoxin és származékaiInfo
- Publication number
- HUE061429T2 HUE061429T2 HUE17742898A HUE17742898A HUE061429T2 HU E061429 T2 HUE061429 T2 HU E061429T2 HU E17742898 A HUE17742898 A HU E17742898A HU E17742898 A HUE17742898 A HU E17742898A HU E061429 T2 HUE061429 T2 HU E061429T2
- Authority
- HU
- Hungary
- Prior art keywords
- derivatives
- botulinum neurotoxin
- novel
- novel botulinum
- neurotoxin
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662360239P | 2016-07-08 | 2016-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE061429T2 true HUE061429T2 (hu) | 2023-06-28 |
Family
ID=59384231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17742898A HUE061429T2 (hu) | 2016-07-08 | 2017-07-07 | Új botulinum neurotoxin és származékai |
Country Status (21)
Country | Link |
---|---|
US (2) | US11286473B2 (hu) |
EP (2) | EP3481852B1 (hu) |
JP (2) | JP7158371B2 (hu) |
KR (1) | KR102530925B1 (hu) |
CN (1) | CN109803980B (hu) |
AU (2) | AU2017292922B9 (hu) |
BR (1) | BR112019000278A2 (hu) |
CA (1) | CA3030155A1 (hu) |
DK (1) | DK3481852T3 (hu) |
EA (1) | EA201990229A1 (hu) |
ES (1) | ES2939001T3 (hu) |
FI (1) | FI3481852T3 (hu) |
HU (1) | HUE061429T2 (hu) |
IL (2) | IL263754B2 (hu) |
MX (1) | MX2019000151A (hu) |
PL (1) | PL3481852T3 (hu) |
PT (1) | PT3481852T (hu) |
SG (2) | SG11201811338VA (hu) |
UA (1) | UA125965C2 (hu) |
WO (1) | WO2018009903A2 (hu) |
ZA (1) | ZA201900341B (hu) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2655614B1 (en) | 2010-12-22 | 2017-03-15 | President and Fellows of Harvard College | Continuous directed evolution |
CN104870468B (zh) | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
US10920208B2 (en) | 2014-10-22 | 2021-02-16 | President And Fellows Of Harvard College | Evolution of proteases |
US11299729B2 (en) | 2015-04-17 | 2022-04-12 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
ES2762951T3 (es) * | 2015-04-24 | 2020-05-26 | Consiglio Nazionale Ricerche | Nuevo uso terapéutico de la neurotoxina botulínica serotipo A |
US10392674B2 (en) | 2015-07-22 | 2019-08-27 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
WO2017015559A2 (en) | 2015-07-23 | 2017-01-26 | President And Fellows Of Harvard College | Evolution of bt toxins |
US10612011B2 (en) | 2015-07-30 | 2020-04-07 | President And Fellows Of Harvard College | Evolution of TALENs |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3458472B1 (en) * | 2016-05-16 | 2021-10-20 | President and Fellows of Harvard College | Method for purification and activation of botulinum neurotoxin |
CA3030155A1 (en) * | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11040090B2 (en) * | 2016-12-08 | 2021-06-22 | Prime Bio, Inc | Botulinum neurotoxin compositions |
US11447809B2 (en) | 2017-07-06 | 2022-09-20 | President And Fellows Of Harvard College | Evolution of tRNA synthetases |
WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS |
WO2019067815A2 (en) * | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
WO2019152380A1 (en) | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
WO2019241649A1 (en) | 2018-06-14 | 2019-12-19 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
BR112021005774A2 (pt) | 2018-09-28 | 2021-07-06 | Inst Of Molecular And Cell Biology Biomedical Sciences Insts | ensaios de neurotoxina de clostridiana à base de célula |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
WO2020219358A2 (en) * | 2019-04-17 | 2020-10-29 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
GB201907016D0 (en) | 2019-05-17 | 2019-07-03 | Ipsen Biopharm Ltd | Screening method to determine suitability for participation in a clinical trial |
US20220259269A1 (en) * | 2019-07-15 | 2022-08-18 | President And Fellows Of Harvard College | Evolved botulinum neurotoxins and uses thereof |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
CN110938150B (zh) * | 2019-12-16 | 2021-08-31 | 中国人民解放军军事科学院军事医学研究院 | E型肉毒毒素重组l-hn抗原的制备方法及其应用 |
CN114269932A (zh) * | 2019-12-18 | 2022-04-01 | Mvrix株式会社 | 肉毒神经毒素的安全制备方法 |
US20240082369A1 (en) * | 2020-12-21 | 2024-03-14 | Children's Medical Center Corporation | Improved receptor-binding domain of botulinum neurotoxin a and uses thereof |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
CN113495106B (zh) * | 2021-02-10 | 2023-08-25 | 中国人民解放军军事科学院军事医学研究院 | 样品检测方法 |
CN114957482A (zh) * | 2021-02-26 | 2022-08-30 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
WO2022197623A1 (en) * | 2021-03-15 | 2022-09-22 | Children's Medical Center Corporation | Engineered botulinum neurotoxin a protease domain with improved efficacy |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
WO2022208091A1 (en) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
WO2022228443A1 (en) * | 2021-04-26 | 2022-11-03 | Shanghaitech University | Intramuscular compositions of botulinum neurotoxins |
JP2023024408A (ja) * | 2021-08-06 | 2023-02-16 | 花王株式会社 | Snareを活用した核酸構築物 |
CA3234608A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
KR20230171400A (ko) * | 2022-06-10 | 2023-12-20 | (주)메디톡스 | 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드 |
CN115785237B (zh) * | 2022-09-01 | 2023-06-16 | 上海蓝晶生物科技有限公司 | 一种重组肉毒杆菌毒素及其制备方法 |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
EP1086702B1 (en) | 1994-05-09 | 2005-04-13 | BINDER, William J. | Presynaptic neurotoxins for treatment of migraine headache |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
JP5178009B2 (ja) * | 2003-12-19 | 2013-04-10 | ウィスコンシン アルムニ リサーチ ファンデイション | ボツリヌス神経毒素検出のための方法および複合体 |
EP2153848A3 (en) * | 2005-01-27 | 2010-07-21 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins |
DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
CN100577149C (zh) * | 2006-12-21 | 2010-01-06 | 北京民海生物科技有限公司 | 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方 |
US8486422B2 (en) * | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
KR20120107988A (ko) | 2009-12-16 | 2012-10-04 | 알러간, 인코포레이티드 | 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소 |
JP6148979B2 (ja) * | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドAllergan,Incorporated | 分解性クロストリジウム毒素 |
WO2012041761A2 (en) * | 2010-09-28 | 2012-04-05 | Merz Pharma Gmbh & Co. Kgaa | Botulinum neurotoxin polypeptides exhibiting a prolonged activity |
EP3372239B1 (en) * | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
EP3822286A1 (en) * | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
EP3274364B1 (en) * | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
US11753633B2 (en) * | 2015-08-27 | 2023-09-12 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
KR20190025906A (ko) * | 2016-06-08 | 2019-03-12 | 칠드런'즈 메디컬 센터 코포레이션 | 조작된 보툴리눔 신경독소 |
CA3030155A1 (en) | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
US11117935B2 (en) * | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
WO2018073370A1 (en) * | 2016-10-21 | 2018-04-26 | Toxogen Gmbh | A functional detection assay devoid of antibodies for serotyping of botulinum neurotoxins |
US20190364907A1 (en) | 2017-07-21 | 2019-12-05 | The Regents Of The University Of California | Compositions of mosquitocidal clostridial proteins and methods of use |
WO2019067815A2 (en) | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
WO2019152380A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
WO2019243376A1 (en) * | 2018-06-18 | 2019-12-26 | Ipsen Biopharm Limited | Intramuscular injection of botulinum toxin for the treatment of vulvodynia |
BR112021005774A2 (pt) * | 2018-09-28 | 2021-07-06 | Inst Of Molecular And Cell Biology Biomedical Sciences Insts | ensaios de neurotoxina de clostridiana à base de célula |
GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
-
2017
- 2017-07-07 CA CA3030155A patent/CA3030155A1/en active Pending
- 2017-07-07 PL PL17742898.4T patent/PL3481852T3/pl unknown
- 2017-07-07 HU HUE17742898A patent/HUE061429T2/hu unknown
- 2017-07-07 WO PCT/US2017/041255 patent/WO2018009903A2/en active Application Filing
- 2017-07-07 KR KR1020197003414A patent/KR102530925B1/ko active IP Right Grant
- 2017-07-07 US US16/315,698 patent/US11286473B2/en active Active
- 2017-07-07 SG SG11201811338VA patent/SG11201811338VA/en unknown
- 2017-07-07 IL IL263754A patent/IL263754B2/en unknown
- 2017-07-07 JP JP2019500553A patent/JP7158371B2/ja active Active
- 2017-07-07 BR BR112019000278-2A patent/BR112019000278A2/pt unknown
- 2017-07-07 EA EA201990229A patent/EA201990229A1/ru unknown
- 2017-07-07 UA UAA201900267A patent/UA125965C2/uk unknown
- 2017-07-07 FI FIEP17742898.4T patent/FI3481852T3/fi active
- 2017-07-07 MX MX2019000151A patent/MX2019000151A/es unknown
- 2017-07-07 EP EP17742898.4A patent/EP3481852B1/en active Active
- 2017-07-07 PT PT177428984T patent/PT3481852T/pt unknown
- 2017-07-07 AU AU2017292922A patent/AU2017292922B9/en active Active
- 2017-07-07 SG SG10201912102WA patent/SG10201912102WA/en unknown
- 2017-07-07 EP EP22211723.6A patent/EP4212545A1/en active Pending
- 2017-07-07 DK DK17742898.4T patent/DK3481852T3/da active
- 2017-07-07 ES ES17742898T patent/ES2939001T3/es active Active
- 2017-07-07 IL IL298102A patent/IL298102A/en unknown
- 2017-07-07 CN CN201780042152.XA patent/CN109803980B/zh active Active
-
2019
- 2019-01-17 ZA ZA2019/00341A patent/ZA201900341B/en unknown
-
2021
- 2021-12-20 US US17/555,570 patent/US20220177867A1/en active Pending
-
2022
- 2022-05-09 JP JP2022076994A patent/JP7402916B2/ja active Active
- 2022-05-16 AU AU2022203264A patent/AU2022203264B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201900341B (en) | A novel botulinum neurotoxin and its derivatives | |
HK1249119A1 (zh) | 工程改造的肉毒桿菌神經毒素 | |
IL263058A (en) | Engineered botulinum neurotoxins | |
IL253939B (en) | cysteine protease | |
IL253938A0 (en) | cysteine protease | |
IL253429B (en) | A container filled with botulinum toxin | |
PL3411389T3 (pl) | Nowe proteazy streptokokowe | |
HK1217173A1 (zh) | 含有肉毒杆菌神經毒素的藥物組合物及其應用 | |
GB201621111D0 (en) | Neurotoxins | |
IL252749A0 (en) | A container filled with botulinum toxin | |
IL266577A (en) | Protease sensor compounds | |
EP3615669A4 (en) | BOTULINIC NEUROTOXINS PRODUCTION PROCESSES | |
DK3142386T3 (da) | Tætningsørestykke | |
PL3458583T3 (pl) | Proteazy o polepszonej skuteczności | |
GB201609127D0 (en) | Protease variants and uses thereof | |
GB201703470D0 (en) | Protease variants and uses thereof | |
GB201603572D0 (en) | Reverse text for android | |
TH1601003724A (th) | ชิ้นส่วนหมุดและอุปกรณ์ควบคุมการเลี้ยว | |
TH1501001832B (th) | ผลิตภัณฑ์สวมใส่ชนิดดึงสวม |